- $17.2 BnWorld market, 2023
- $74.6 BnProjected, 2033
- 15.8%Growth a year (CAGR)
- 3,045Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$7.2 Bn
13.8% a year · 42% of the world -
2
China
$1.4 Bn
17.3% a year · 8% of the world -
3
Canada
$1.4 Bn
15.8% a year · 8% of the world -
4
Japan
$1.1 Bn
16.3% a year · 6.2% of the world -
5
Germany
$630 Mn
14% a year · 3.7% of the world -
6
France
$473 Mn
14.8% a year · 2.8% of the world -
7
UK
$447 Mn
13.8% a year · 2.6% of the world -
8
Brazil
$430 Mn
16.8% a year · 2.5% of the world -
9
Italy
$413 Mn
15.3% a year · 2.4% of the world -
10
Ecuador
$344 Mn
16.4% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)
Spain
EgyptPatient Support Programs (PSP) by country and region
India
Saudi Arabia
Mexico
Australia
South Africa
UAE
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 280 papers since 2021
- Characterization of Patients Living with Generalized Myasthenia Gravis Initiating Rozanolixizumab in the USA. Drugs - real world outcomes, 2026
- Practical tips for implementing SGLT2i in practice. Postgraduate medicine, 2026
- Cardiologists' perspectives on sociocultural and structural factors shaping cardiovascular genetic testing. Public health genomics, 2026
- A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program. Crohn's & colitis 360, 2026
- Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world inflammatory bowel disease cohort. Journal of the Canadian Association of Gastroenterology, 2026
Compare Patient Support Programs (PSP) side by side
Key companies in Patient Support Programs (PSP)
Allscripts Healthcare, LLC
Orion Health
Cerner Corporation
McKesson Corporation
athenahealth, Inc.
IBM
Medecision
GetWellNetwork, Inc.
MEDHOST
Lincor
IQVIA
Wolters Kluwer N.V.
Quick answers
How big is the Patient Support Programs (PSP) market?
The world Patient Support Programs (PSP) market was worth about $17.2 Bn in 2023 and is projected to reach $74.6 Bn by 2033, growing 15.8% a year (CAGR).
Which country has the largest Patient Support Programs (PSP) market?
The US is the largest of the 24 countries we cover, at $7.2 Bn in 2023. India grows fastest, at 18.8% a year.
How many clinical trials are running in Patient Support Programs (PSP)?
ClinicalTrials.gov lists 3,045 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Patient Support Programs (PSP)?
PubMed lists about 280 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.